Alexion
Alexion moves to bolster patent protection of Soliris
August 17, 2017Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris
Soliris brought in net sales of $2.8 billion last year for Alexion, meaning it accounted for close to 90% of …
NICE agrees approval deal for ultra-rare juvenile bone disease
July 5, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease …
Alexion secures ex-Biogen Chief Financial Officer
June 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alexion, Biogen, appointment
Alexion Pharmaceuticals has announced that it has snatched up Biogen’s long-serving Chief Financial Officer Paul Clancy and will instate him …
Alexion leadership uncertainty ends as ex-Baxalta CEO steps in
March 28, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alexion, CEO
Alexion had been left in leadership limbo for the beginning of the year, as former CEO and CFO left under …
Alexion hits out at NICE ruling on Strensiq
February 8, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …
Alexion loses CEO & CFO as internal investigation continues
December 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alexion
Alexion Pharmaceuticals has revealed that its CEO David Hallal (pictured) and CFO Vikas Sinha have resigned effective immediately in connection …
Rare challenges: Meeting patient needs and delivering medical innovation in ultra-rare diseases
December 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alexion, ultra rare disease, ultra-rare disease
Dr Emma Harvey, senior medical director at Alexion Pharmaceuticals UK, shares her views on the challenges of working in the …
Alexion begins internal probe into sales practices
November 11, 2016Medical Communications Alexion, sales practices
Alexion Pharmaceuticals released a statement that it was to begin conducting an internal investigation into sales practices for Soliris (eculizumb) …
Weekly Movers: Lion Biotech, Adamis, Sarepta…
June 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta
Drug trial results remained the important theme over the past week with several companies announcing key study results. The trial …
More evidence required for Alexion’s Kanuma, says NICE
February 18, 2016Medical Communications, Research and Development Alexion, Kanuma, LAL-D, rare diseases
NICE says it needs additional trial data before it can recommend Alexion’s enzyme replacement therapy Kanuma (sebelipase alfa) for the …
NICE turns down bone disorder drug for NHS
December 3, 2015Research and Development Alexion, NICE, Strensiq
NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …
Alexion to challenge Canadian price of Soliris in court
September 28, 2015Sales and Marketing Alexion, Canada, Drug pricing, Patented Medicine Prices Review Board, eculizumab, soliris
Alexion Pharmaceuticals is taking the Canadian government to court for its attempt to lower the price of the rare disease …
Alexion scores double EU approval
September 1, 2015Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease
Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …
EMA waves through a raft of drug recommendations
June 26, 2015Research and Development, Sales and Marketing AbbVie, Alexion, CHMP, EMA, Novartis, Novo Nordisk, brett wells
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended several treatments for marketing …
Alexion plans big expansion in Ireland
May 12, 2015Manufacturing and Production, Sales and Marketing Alexion, Dublin, Ireland, soliris
Alexion Pharmaceuticals is significantly expanding its operations in Ireland by building the US firm’s first ever biologics manufacturing facility outside …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
